These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22553356)

  • 1. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.
    Chen W; Feng Y; Zhao Q; Zhu Z; Dimitrov DS
    Mol Cancer Ther; 2012 Jul; 11(7):1400-10. PubMed ID: 22553356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques.
    Feng Y; Zhao Q; Chen W; Wang Y; Crowder K; Dimitrov DS
    Exp Mol Pathol; 2014 Dec; 97(3):359-67. PubMed ID: 25220345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.
    Zhao Q; Feng Y; Zhu Z; Dimitrov DS
    Mol Cancer Ther; 2011 Sep; 10(9):1677-85. PubMed ID: 21750218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function.
    Feng Y; Zhu Z; Xiao X; Choudhry V; Barrett JC; Dimitrov DS
    Mol Cancer Ther; 2006 Jan; 5(1):114-20. PubMed ID: 16432169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of new monoclonal antibodies to human insulin-like growth factor-II and their application in western immunoblot analysis.
    Enjoh T; Hizuka N; Perdue JF; Takano K; Fujiwara H; Higashihashi N; Marumoto Y; Fukuda I; Sakano K
    J Clin Endocrinol Metab; 1993 Aug; 77(2):510-7. PubMed ID: 7688378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
    Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
    Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for species and ligand specificity of a monoclonal antibody raised against human IGF-I.
    Van Wyk JJ; Bruton ET
    Endocrinology; 1997 Oct; 138(10):4521-2. PubMed ID: 9322977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody.
    Kasturirangan S; Rainey GJ; Xu L; Wang X; Portnoff A; Chen T; Fazenbaker C; Zhong H; Bee J; Zeng Z; Jenne C; Wu H; Gao C
    J Biol Chem; 2017 Mar; 292(10):4361-4370. PubMed ID: 28100773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
    Friedbichler K; Hofmann MH; Kroez M; Ostermann E; Lamche HR; Koessl C; Borges E; Pollak MN; Adolf G; Adam PJ
    Mol Cancer Ther; 2014 Feb; 13(2):399-409. PubMed ID: 24296829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding specificities and transducing function of the different molecular weight forms of insulin-like growth factor-II (IGF-II) on IGF-I receptors.
    Perdue JF; LeBon TR; Kato J; Hampton B; Fujita-Yamaguchi Y
    Endocrinology; 1991 Dec; 129(6):3101-8. PubMed ID: 1659523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
    Kusada Y; Morizono T; Matsumoto-Takasaki A; Sakai K; Sato S; Asanuma H; Takayanagi A; Fujita-Yamaguchi Y
    J Biochem; 2008 Jan; 143(1):9-19. PubMed ID: 17956902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding.
    Tamm A; Schmidt RE
    J Immunol; 1996 Aug; 157(4):1576-81. PubMed ID: 8759741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells.
    De Leon DD; Wilson DM; Powers M; Rosenfeld RG
    Growth Factors; 1992; 6(4):327-36. PubMed ID: 1340210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.